Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceDNA-based anti-SARS-CoV-2 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- Generation Bio
- Modality
- Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
A **ceDNA-based anti-SARS-CoV-2 monoclonal antibody** refers to an experimental gene-encoded antibody product in which a closed-ended DNA construct is used to drive in vivo expression of a monoclonal antibody directed against **SARS-CoV-2**, most plausibly against the viral **spike protein** based on available public descriptions of anti-SARS-CoV-2 antibody programs using DNA delivery. Publicly available materials indicate that **Generation Bio** disclosed a **preclinical ceDNA-based approach** intended to enable persistent hepatic expression of therapeutic anti-SARS-CoV-2 antibodies, but the specific antibody sequence, product name, and exact molecular identity have not been clearly identified from accessible sources. As a result, this appears to describe a **platform-defined investigational product concept** rather than a well-resolved named drug candidate. The intended mechanism would be sustained in vivo production of a neutralizing monoclonal antibody that binds SARS-CoV-2 spike and blocks viral entry, with potential use for COVID-19 prevention or treatment.
- Other names
- ceDNA-based anti-SARS-CoV-2 monoclonal antibody
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on ceDNA-based anti-SARS-CoV-2 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceDNA-based anti-SARS-CoV-2 monoclonal antibody.